Clinical observation of Ascending Lucidity Descending Turbidity Decoction combined with bevacizumab intracavitary injection in the treatment of malignant serous cavities effusion

Shenzhen Hospital of Beijing University of Traditional Chinese Medicine (Longgang)0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. The following diagnostic criteria were met
•(1) Patients with pathologically confirmed malignancies, but not squamous cell carcinoma;
•(2) Ultrasound or CT examination showed a large number of pleural effusion, pericardial effusion or peritoneal effusion;
•(3) Malignant tumor cells were found in the effusion.
•2. Those patients who had no intraluminal injection of anticancer drugs or sclerosing agents one month before enrollment;
•3. The patients with KPS score >= 60 were older than 18 years old, and the expected survival time was more than 3 months;
•4. Patients without major organ system dysfunction;
•5. Patients with a history of chemotherapy had stopped chemotherapy for more than 4 weeks.

•1. Patients with previous history of allergy to biological agents;
•2. No detectable lesions were found in imaging;
•3. Patients with metastasis to the central nervous system;
•4. Patients with major organ dysfunction, such as congestive heart failure, malignant arrhythmia, angina pectoris requiring long-term medication, valvular heart disease, myocardial infarction and intractable hypertension;
•5. Pregnant or lactating women;
•6. Subjects with previously refractory mental illness.

发起方

Shenzhen Hospital of Beijing University of Traditional Chinese Medicine (Longgang)